Historical Valuation
Biontech SE (BNTX) is now in the Fair zone, suggesting that its current forward PS ratio of 9.14 is considered Fairly compared with the five-year average of -5.28. The fair price of Biontech SE (BNTX) is between 50.93 to 100.11 according to relative valuation methord.
Relative Value
Fair Zone
50.93-100.11
Current Price：98.85
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Biontech SE (BNTX) has a current Price-to-Book (P/B) ratio of 1.07. Compared to its 3-year average P/B ratio of 1.19 , the current P/B ratio is approximately -9.73% higher. Relative to its 5-year average P/B ratio of 3.60, the current P/B ratio is about -70.21% higher. Biontech SE (BNTX) has a Forward Free Cash Flow (FCF) yield of approximately -2.50%. Compared to its 3-year average FCF yield of 16.60%, the current FCF yield is approximately -115.03% lower. Relative to its 5-year average FCF yield of 13.93% , the current FCF yield is about -117.91% lower.
P/B
Median3y
1.19
Median5y
3.60
FCF Yield
Median3y
16.60
Median5y
13.93
Competitors Valuation Multiple
AI Analysis for BNTX
The average P/S ratio for BNTX competitors is 9.44, providing a benchmark for relative valuation. Biontech SE Corp (BNTX.O) exhibits a P/S ratio of 9.14, which is -3.14% above the industry average. Given its robust revenue growth of 22.02%, this premium appears sustainable.
Performance Decomposition
AI Analysis for BNTX
1Y
3Y
5Y
Market capitalization of BNTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BNTX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BNTX currently overvalued or undervalued?
Biontech SE (BNTX) is now in the Fair zone, suggesting that its current forward PS ratio of 9.14 is considered Fairly compared with the five-year average of -5.28. The fair price of Biontech SE (BNTX) is between 50.93 to 100.11 according to relative valuation methord.
What is Biontech SE (BNTX) fair value?
BNTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Biontech SE (BNTX) is between 50.93 to 100.11 according to relative valuation methord.
How does BNTX's valuation metrics compare to the industry average?
The average P/S ratio for BNTX's competitors is 9.44, providing a benchmark for relative valuation. Biontech SE Corp (BNTX) exhibits a P/S ratio of 9.14, which is -3.14% above the industry average. Given its robust revenue growth of 22.02%, this premium appears sustainable.
What is the current P/B ratio for Biontech SE (BNTX) as of Jan 09 2026?
As of Jan 09 2026, Biontech SE (BNTX) has a P/B ratio of 1.07. This indicates that the market values BNTX at 1.07 times its book value.
What is the current FCF Yield for Biontech SE (BNTX) as of Jan 09 2026?
As of Jan 09 2026, Biontech SE (BNTX) has a FCF Yield of -2.50%. This means that for every dollar of Biontech SE’s market capitalization, the company generates -2.50 cents in free cash flow.
What is the current Forward P/E ratio for Biontech SE (BNTX) as of Jan 09 2026?
As of Jan 09 2026, Biontech SE (BNTX) has a Forward P/E ratio of -17.54. This means the market is willing to pay $-17.54 for every dollar of Biontech SE’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Biontech SE (BNTX) as of Jan 09 2026?
As of Jan 09 2026, Biontech SE (BNTX) has a Forward P/S ratio of 9.14. This means the market is valuing BNTX at $9.14 for every dollar of expected revenue over the next 12 months.